To meet the Trump Administration’s Operation Warp Speed goals, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD) today announced an agreement with AstraZeneca for late-stage development and large-scale manufacturing of the company’s COVID-19 investigational product AZD7442, a cocktail of two monoclonal antibodies, that may help treat or prevent infection with SARS-CoV-2, the coronavirus that causes COVID-19.
{iframe}https://www.defense.gov/Newsroom/Releases/Release/Article/2380882/trump-administration-expands-collaboration-with-astrazeneca-to-develop-and-manu/{/iframe}